These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 37787068)
1. Hypertrophic cardiomyopathy: investigational drugs inhibiting myosin and upcoming agents. Hajj Ali A; Mehra N; Desai MY Expert Opin Investig Drugs; 2023; 32(9):849-853. PubMed ID: 37787068 [TBL] [Abstract][Full Text] [Related]
2. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D; Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100 [TBL] [Abstract][Full Text] [Related]
3. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Dong T; Nissen S; Ospina S; Desai MY Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857 [TBL] [Abstract][Full Text] [Related]
4. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641 [TBL] [Abstract][Full Text] [Related]
5. Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond. Gaballa A; Jadam S; Desai MY Expert Opin Pharmacother; 2024 May; 25(7):915-924. PubMed ID: 38813944 [TBL] [Abstract][Full Text] [Related]
6. Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy. Rosenzveig A; Garg N; Rao SJ; Kanwal AK; Kanwal A; Aronow WS; Martinez MW Expert Opin Pharmacother; 2023; 24(12):1349-1360. PubMed ID: 37272195 [TBL] [Abstract][Full Text] [Related]
7. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. Sebastian SA; Padda I; Lehr EJ; Johal G Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885 [TBL] [Abstract][Full Text] [Related]
8. Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide. Willeford A; Silva Enciso J Pharmacotherapy; 2023 Dec; 43(12):1397-1404. PubMed ID: 37688422 [TBL] [Abstract][Full Text] [Related]
9. Obstructive hypertrophic cardiomyopathy: a review of new therapies. Mehra N; Ali AH; Desai MY Future Cardiol; 2023 Oct; 19(13):661-670. PubMed ID: 37933625 [TBL] [Abstract][Full Text] [Related]
10. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Tower-Rader A; Ramchand J; Nissen SE; Desai MY Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741 [TBL] [Abstract][Full Text] [Related]
11. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217 [TBL] [Abstract][Full Text] [Related]
12. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment]. Lancellotti P; de Marneffe N; Scheen A Rev Med Liege; 2024 Feb; 79(2):120-128. PubMed ID: 38356430 [TBL] [Abstract][Full Text] [Related]
13. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy]. Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066 [TBL] [Abstract][Full Text] [Related]
14. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management. Sykuta A; Yoon CH; Baldwin S; Rine NI; Young M; Smith A Ann Pharmacother; 2024 Mar; 58(3):273-285. PubMed ID: 37329113 [TBL] [Abstract][Full Text] [Related]
15. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]